Document is current
Any future updates will be listed below
-
Authors
Bergmann, Natasha C.
Lund, Asger
Gasbjerg, Lærke S.
Meessen, Emma C. E.
Andersen, Maria M.
Bergmann, Sigrid
Hartmann, Bolette
Holst, Jens J.
Jessen, Lene
Christensen, Mikkel B.
Vilsbøll, Tina
Knop, Filip K. https://orcid.org/0000-0002-2495-5034
-
Funding
Funding for this research was provided by:
The Vissing Foundation
The Innovation Fund Denmark
- License Information
-
More Information
Article History
Received: 12 November 2018
Accepted: 7 December 2018
First Online: 25 January 2019
Duality of interest
: NCB holds an unrestricted grant from the Innovation Fund Denmark and is employed as a PhD student at Zealand Pharma in collaboration with Steno Diabetes Center Copenhagen, Gentofte Hospital. LSG is a minority shareholder in Antag Therapeutics. LJ is employee of Zealand Pharma. JJH has served on advisory panels for GlaxoSmithKline, Novo Nordisk, Zealand Pharma, AstraZeneca, MSD, Intarcia and Hanmi and as a consultant for Novo Nordisk, and has received research support from Merck, Sharp & Dome. FKK has received lecture fees from, participated in advisory boards of, consulted for and/or received research grants from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD/Merck, Novo Nordisk, Sanofi and Zealand Pharma, and is a minority shareholder in Antag Therapeutics. AL, ECEM, MMA, SB, BH, MC and TV declare no duality of interest associated with their contribution to this manuscript.
